MENU
+Compare
CANF
Stock ticker: ASE
AS OF
Sep 3 closing price
Price
$0.66
Change
-$0.00 (-0.00%)
Capitalization
13.02M

CANF Can-Fite BioPharma Ltd Forecast, Technical & Fundamental Analysis

Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company... Show more

Industry: #Biotechnology
CANF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for CANF with price predictions
Sep 03, 2025

CANF sees its Stochastic Oscillator ascends from oversold territory

On August 21, 2025, the Stochastic Oscillator for CANF moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 66 instances where the indicator left the oversold zone. In of the 66 cases the stock moved higher in the following days. This puts the odds of a move higher at over .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CANF's RSI Indicator exited the oversold zone, of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on September 02, 2025. You may want to consider a long position or call options on CANF as a result. In of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for CANF just turned positive on August 14, 2025. Looking at past instances where CANF's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CANF advanced for three days, in of 207 cases, the price rose further within the following month. The odds of a continued upward trend are .

CANF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CANF declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for CANF entered a downward trend on August 28, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.305) is normal, around the industry mean (19.946). P/E Ratio (0.000) is within average values for comparable stocks, (51.910). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.076). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (11.710) is also within normal values, averaging (324.828).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. CANF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CANF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
CANF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a developer of biopharmaceuticals for treatment of autoimmune diseases and cancers

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
26 Ben Gurion Street
Phone
+972 39241114
Employees
5
Web
http://www.canfite.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BIVI1.670.09
+5.70%
BioVie Inc
TU16.470.13
+0.80%
Telus Corp
RBBN4.01-0.01
-0.25%
Ribbon Communications
TGLS70.45-0.33
-0.47%
Tecnoglass
AEYE12.03-0.32
-2.59%
AudioEye

CANF and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CANF has been loosely correlated with OABI. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if CANF jumps, then OABI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CANF
1D Price
Change %
CANF100%
-0.06%
OABI - CANF
34%
Loosely correlated
-3.80%
ASMB - CANF
27%
Poorly correlated
-0.95%
CYTK - CANF
27%
Poorly correlated
+0.75%
RNA - CANF
27%
Poorly correlated
+0.76%
IVF - CANF
26%
Poorly correlated
+0.65%
More